Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
View Patent ↗The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.
1. A method of treating a skin, mucosal, or body cavity disorder comprising administering to skin, mucosal, or body cavity a composition comprising:
a) about 1% to about 5% of a minocycline;
b) one or more short chain alcohols comprising ethanol;
c) about 2% to about 50% by weight of the composition of one or more protic polar solvents comprising propylene glycol;
d) one or more polymeric agents comprising a cellulose ether; e) one or more modulating agents comprising an antioxidizing agent;
f) a metal; and
g) an essential oil;
wherein the composition is essentially free of fatty alcohol;
wherein the composition is surfactant free; and
wherein the composition is waterless.
2. The method according to claim 1 , wherein the disorder is selected from an infection, an inflammation, acne, rosacea, psoriasis, eczema, and atopic dermatitis.
3. The method according to claim 2 , wherein the disorder is an infection or an inflammation.
4. The method according to claim 2 , wherein the disorder is acne.
5. The method according to claim 2 , wherein the disorder is rosacea.
6. The method according to claim 1 , wherein the minocycline is dissolved in the composition.
7. The method according to claim 6 , wherein the minocycline is minocycline hydrochloride.
8. The method according to claim 1 , wherein the composition is essentially free of fatty acid.
9. The method according to claim 1 , comprising about 1% of the minocycline by weight of the composition.
10. The method according to claim 1 , wherein the short chain alcohol is present in an amount of at least 55% by weight of the composition.
11. The method according to claim 1 , wherein the protic polar solvent is about 12% to about 30% by weight of the composition.
12. The method according to claim 1 , wherein the cellulose ether is a hydroxypropyl cellulose.
13. The method composition according to claim 1 , wherein the cellulose ether is present in an amount ranging from about 0.5% to about 1% by weight of the composition.
14. The method according to claim 1 , wherein the modulating agent is present in an amount ranging from about 0.1% to about 10% by weight of the composition.
15. The method according to claim 1 , wherein the composition further comprises one or more additional therapeutic agents.
16. The method according to claim 15 , wherein the additional therapeutic agent comprises an antibacterial agent, an antibiotic, an antidermatitis agent, an antifungal agent, an anti-infective agent, an antiinflammatory agent, an antiirritant, an antimicrobial agent, an antiviral agent, a retinoid, a vitamin, a peptide, an antipsoriasis agent, or an antirosacea agent.
17. The method according to claim 16 , wherein the additional therapeutic agent comprises a retinoid, wherein the retinoid comprises tazarotene or adapalene.
18. A method of treating a skin, mucosal, or body cavity disorder comprising administering to skin, mucosal, or body cavity a composition comprising:
a) about 1% to about 5% of a minocycline;
b) one or more short chain alcohols comprising ethanol present in an amount of at least 55% by weight of the composition;
c) about 2% to about 50% by weight of the composition of one or more protic polar solvents comprising propylene glycol;
d) one or more polymeric agents comprising a cellulose ether, wherein the cellulose ether is a hydroxypropyl cellulose present in an amount ranging from about 0.5% to about 1% by weight of the composition;
e) one or more modulating agents comprising an antioxidizing agent present in an amount ranging from about 0.1% to about 10% by weight of the composition;
f) a metal; and
g) an essential oil;
wherein the composition is free or essentially free of fatty alcohol;
wherein the composition is surfactant free; and
wherein the composition is waterless.
19. The method according to claim 18 , wherein the disorder is acne.
20. The method according to claim 18 , wherein the disorder is rosacea.
21. The method according to claim 18 , wherein the minocycline is minocycline hydrochloride.
22. The method according to claim 18 , comprising about 1% of the minocycline by weight of the composition.
23. The method according to claim 18 , wherein the composition further comprises one or more additional therapeutic agents.
24. The method according to claim 23 , wherein the additional therapeutic agent comprises an antibacterial agent, an antibiotic, an antidermatitis agent, an antifungal agent, an anti-infective agent, an antiinflammatory agent, an antiirritant, an antimicrobial agent, an antiviral agent, a retinoid, a vitamin, a peptide, an antipsoriasis agent, or an antirosacea agent.
25. The method according to claim 24 , wherein the additional therapeutic agent comprises a retinoid, wherein the retinoid comprises tazarotene or adapalene.
26. The method according to claim 18 , wherein the composition is free or essentially free of fatty acid.